Craig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses some future treatment approaches for patients with aggressive lymphomas, including diffuse large B-cell lymphoma (DLBCL).

Reeder hopes that the community are able to use regimens more like an infusion, dose-adjusted regimen of etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride, and rituximab (EPOCH-R). Future research should determine whether this regimen, or a novel agent such as lenalidomide (Revlimid) or ibrutinib (Imbruvica), will have a benefit for patients with these high-risk lymphomas, should they turn out to be much more effective.

Additionally, researchers are now able to phenotype the large cell lymphomas into the activated B-cell (ABC) type versus the germinal center B-cell type (GCB) type. Researchers hope that these drugs will be beneficial for each of the subtypes and will represent a more individualized approach.  

The 2 subtypes have typically been based on gene expression profiling, Reeder says, adding that it is a tedious process. The various approaches have included immunohistochemistry, the Hans algorithm, and phenotyping either into GCB or ABC. GCB subtypes are likely to have better outcomes with R-CHOP than the non-GCB or ABC types.

Videos

Craig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses some future treatment approaches for patients with aggressive lymphomas, including diffuse large B-cell lymphoma.

Dr. Reeder on Future Treatment Approaches in Aggressive Lymphomas

Craig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses the role that R-CHOP will continue to have in the treatment of patients with aggressive lymphomas, in an interview during the 2016 

 State of the Science Summit on Treatment of Hematologic Malignancies.

While many agents have efficacy in patients with aggressive lymphomas, Reeder explains that regimens adding cytotoxic drugs to the R-CHOP regimen were less likely to demonstrate benefit. The addition of small molecular inhibitors though, he adds, could have very different results.

Clinical trial results anticipated to be presented at the 2016 ASH Annual Meeting will compare the efficacy between R-CHOP and dose-adjusted EPOG-R, which is infusion chemotherapy, he adds.

Craig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses the role that R-CHOP will continue to have in the treatment of patients with aggressive lymphomas. 

Craig B. Reeder, MD

Articles

Dr. Reeder on Future Treatment Approaches in Aggressive Lymphomas

Dr. Reeder on Evolving Role of R-CHOP in Aggressive Lymphomas